Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.

This study has been completed.
Information provided by:
Renovo Identifier:
First received: February 18, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
An exploratory Phase-II trial with intradermal RN1001 (Avotermin) to investigate scar prevention and reduction and acceleration of healing. The trial has an additional objective to evaluate several different scar assessment techniques that can be used in future clinical trials in the prevention and reduction of scarring.

Condition Intervention Phase
Drug: Avotermin
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Trial to Investigate the Accelerated Wound Healing and Antiscarring Potential, Safety, Toleration and Systemic Exposure of Intradermal RN1001 (Avotermin) in Male and Female Subjects Aged 60 Years and Over.

Resource links provided by NLM:

Further study details as provided by Renovo:

Primary Outcome Measures:
  • Evaluation of scar appearance by an independent panel [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Histological evaluation of wound healing [ Time Frame: 3 days ]
  • Adverse event occurance [ Time Frame: 6 months ]

Enrollment: 42
Study Start Date: September 2002
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
5ng Avotermin
Drug: Avotermin
Intradermal administration
Other Name: Juvista
Experimental: 2
50ng Avotermin
Drug: Avotermin
Intradermal administration
Other Name: Juvista
Experimental: 3
100ng Avotermin
Drug: Avotermin
Intradermal administration
Other Name: Juvista
Placebo Comparator: 4
Drug: Placebo
No Intervention: 5
Standard Care

Detailed Description:
Double blind, randomised, Placebo and Standard Care controlled, single centre study. Each subject receives a total of 6 wounds, two incisions and four punch biopsies. Each subject serves as their own control, i.e. Arm 1 incisions/biopsies randomly received one of two treatments and Arm 2 incisions/biopsies received the same treatments as for Arm 1 but in reverse. The randomisation of the treatment allowed for control of possible positional effects on healing/scarring. Healed scars from incisional wounds excised from Arm 1 and Arm 2 after 6 months for histological analysis.

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinically healthy, male and female subjects aged 60 years and over. All females will be at least 2 years post menopausal.
  • Weight between 50 and 150kg or a body mass index within the permitted range for their height using Quetelet's index-weight (kg)/height²(m). The permitted index is between 15 - 35 kg/m2.

Exclusion Criteria:

  • Subjects who on direct questioning and physical examination have a history or evidence of hypertrophic or keloid scarring or with tattoos or previous scars in the area to be biopsied.
  • Subjects with a personal history of a bleeding disorder.
  • Subjects with a skin disorder that is chronic or currently active and which the investigator considers will adversely affect the healing the acute wounds or involves the areas to be examined in this trial.
  • Subjects with any clinically significant medical condition that would impair wound healing including renal, hepatic, haematological, neurological or immune disease.
  • Subjects with a history of clinically significant drug hypersensitivity to lignocaine or allergy to surgical dressings to be used in this trial.
  • Subjects with any clinically significant abnormality following review of pre trial laboratory data and physical examination (see above).
  • Subjects who are taking, or have taken, any investigational drugs, long term oral, topical or inhaled corticosteroid therapy, hormone replacement therapy (HRT) or anti-coagulant drugs in the thirty days prior to Day 0.
  • Subjects who have evidence of drug abuse.
  • Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen or hepatitis C antibody. Subjects with previous vaccination against Hepatitis B are not excluded per se.
  • Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B core antibody and who show less than 10 units per litre of Anti-HBs.
  • Subjects who have previously had a positive result to the test for HIV antibodies, or who admit to belonging to a high-risk group.
  • In the opinion of the investigator, a subject who is not likely to complete the trial for what ever reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00847795

United Kingdom
Renovo CTU
Manchester, United Kingdom, M13 9XX
Sponsors and Collaborators
Principal Investigator: Jonathan Duncan, BS BCh Renovo
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mark Cooper, Renovo Ltd Identifier: NCT00847795     History of Changes
Other Study ID Numbers: RN1001-319-1005
Study First Received: February 18, 2009
Last Updated: February 18, 2009

Additional relevant MeSH terms:
Pathologic Processes processed this record on May 25, 2017